Search
Search
#1. Oral Anticoagulation in Patients with End-stage Kidney ... - NCBI
由 A Hu 著作 · 2018 · 被引用 22 次 — However, investigating patterns of new use of any single oral anticoagulant (among dialysis patients who had not filled any prescriptions ...
#2. Update on the Safety and Efficacy of Oral Anticoagulation in ...
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009;20:2223-2233.
#3. New Oral AntiCoagulants Use in REnal Disease and AF ...
The efficacy and safety of non-vitamin K oral an- ticoagulants (NOACs) in patients with ESRD, includ- ing those on dialysis are unclear and is ...
#4. Novel oral anticoagulants in patients with chronic kidney ...
Novel oral anticoagulants (NOACs) are nowadays often used in patients with AF and CKD, but they display a variable degree of renal ...
#5. Nonvitamin K Anticoagulant Agents in Patients With Advanced ...
Patients on hemodialysis have added bleeding risks from repeated vascular access ... For NOAC dosing, CrCl should be calculated using the ...
#6. Dabigatran and Rivaroxaban Use in Atrial ... - AHA Journals
Prescription of these novel oral anticoagulant drugs (NOAC) in dialysis patients is currently contraindicated because the drugs are cleared via ...
#7. NOAC in CKD
who provided much of the data used in this talk. 3. Page 4. Our Plans Today…… 1. Pharmacology / Epidemiology of NOACs in advanced CKD/dialysis (GFR<30 cc/min).
#8. Clinical Evidence for the Choice of the Direct Oral ... - MDPI
由 R Vio 著作 · 2021 · 被引用 1 次 — European recommendations contraindicate the use of all DOACs in patients with. CrCl < 15 mL/min or on dialysis, whereas US Food and Drug ...
#9. Management of atrial fibrillation in patients with chronic kidney ...
Dabigatran. In AF patients with severe CKD or on dialysis, 38.8% of cardiologists and 43.1% of nephrologists would never consider using ...
#10. Oral Anticoagulation in Dialysis Patients - Alberta Health ...
Fully adjusted = +dialysis vintage, Medicaid eligibility, ... Variation in Facility use of. Antithrombotic Agents in Dialysis ... NOAC in non-valvular AF ...
#11. Rivaroxaban in Chronic Hemodialysis Patients - Karger ...
This is reassuring but also not able to adequately predict the potential risk with chronic use. The greatest risk with anticoagulation is ...
#12. Use of XARELTO in Renal Insufficiency - JanssenMD
A summary of clinical data regarding XARELTO® (rivaroxaban) use in patients with renal insufficiency (end-stage renal disease and hemodialysis).
#13. Anticoagulation in Patients with End-Stage Renal Disease ...
Bleeding risk (ICH) was more pronounced with aspirin use among patients with severe hypertension (pre-dialysis systolic blood pressure >160 mm ...
#14. Newer Oral Anticoagulant in Chronic Kidney Disease - JAPI
Newer oral anticoagulants/ non Vit. K antagonist (NOAC) reduce risk of stroke or systemic embolism and bleeding versus warfarin in patients with AF. The use of ...
#15. Trial to Evaluate Anticoagulation Therapy in Hemodialysis ...
Official Title: RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in ... Warfarin use associates with increased risk for stroke in hemodialysis ...
#16. Dabigatran and Rivaroxaban Use in Atrial ... - ResearchGate
Their use in dialysis patients is discouraged. ... conflicting results for the use of anticoagulation therapy (warfarin and NOACs) in dialysis patients with ...
#17. No Stroke Reduction but Increased Bleeding With OAC in ...
In patients with A-fib who are on chronic dialysis, oral anticoagulation with either warfarin or a direct oral anticoagulant (DOAC) does not ...
#18. Anticoagulation for Dialysis Patients with Atrial Fibrillation
By continuing to use our site, you accept the use of these cookies. To learn more, please visit our Cookie Information. opens in new tab page.
#19. Oral Anticoagulant Treatment of Atrial Fibrillation in Chronic ...
studies to investigate warfarin use in patients on hemodialysis. ... applied) and a single/high-dose NOAC (dabigatran 2x150 mg,.
#20. RENal hemodialysis patients ALlocated apixaban versus ...
It remains unclear if lower apixaban dose (2.5 mg BID) and cessation of aspirin (used in ~40%) would have resulted in lower bleeding compared ...
#21. The use of anticoagulants in chronic kidney disease - Via ...
In hemodialysis patients, the recommended dose ... Use of non- vitamin K antagonist oral anticoagulants (NOACs) in patients.
#22. Oral Anticoagulation in Chronic Kidney ... - Deutsches Ärzteblatt
The Use of Non-Vitamin K-Dependent Anticoagulants and Vitamin K ... of <25 mL/min and for dialysis patients, we regard the use of NOAC—which ...
#23. Nonvitamin K Oral Anticoagulants in Patients With Atrial ...
Search terms used were: “NOAC”, “chronic kidney disease”, “atrial fibrillation”, “dialysis”, “apixaban”, “rivaroxaban”, “edoxaban”, and “dabigatran”.
#24. Influence of Renal Function on the Pharmacokinetics ...
(AF) and ESRD undergoing hemodialysis. ... Hemodialysis removed only 4% of the drug ... 1.73m2 for factor Xa inhibitors), NOAC use is not restricted in.
#25. Chronic kidney disease and arrhythmias - KDIGO
widely used risk scores for the prediction of stroke in dialysis patients are similar to those ... recommend the formal use of bleeding risk.
#26. Clinical outcomes among hemodialysis patients with atrial ...
The use of warfarin was significantly associated with hemorrhagic stroke incidence (HR, 1.593; 95% CI, 1.075-2.360; p = 0.020), while there was ...
#27. Oral Anticoagulants in Patients With Atrial Fibrillation and End ...
Patients on hemodialysis (HD) with AF have additional risk factors ... Dabigatran was the first NOAC approved by the FDA for use in AF in ...
#28. Apixaban Use in Adults with Severe Kidney Disease - ACT ...
This contra-indication pre-dates more recent data on the pharmacokinetics of NOACs in dialysis patients. Apixaban has the least renal excretion of any NOAC. A ...
#29. Is Apixaban Safe and Effective for Patients on Hemodialysis?
Apixaban (Eliquis) is the only NOAC approved for use with creatinine clearance. Novel oral anticoagulants (NOACs) offer an alternative to ...
#30. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K ...
Management of Patients with Non-Dialysis Dependent Chronic Kidney ... Association between use of warfarin for atrial fibrillation and ...
#31. New oral anticoagulants in patients with chronic kidney disease
No accurate data are available in CKD patients who are not on dialysis (Table 1). ... In subgroup analyses, there are no references to the use of NOACs in ...
#32. Novel Oral Anticoagulants (NOACs) in CKD & Dialysis ...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? What is the Evidence? - Dr. Gawad. Oct. 10, 2019. • 25 likes • 2,893 views.
#33. Use of Rivaroxaban and Apixaban, Two Non-Vitamin K ...
To understand the influence of renal function on NOAC use, ... a single dose twice (once prior to dialysis and once after dialysis), ...
#34. Oral Anticoagulation in Chronic Kidney Disease and Atrial ...
For pa- tients with CKD G 4 and a creatinine clearance of. <25 mL/min and for dialysis patients, we regard the use of NOAC—which entails a ...
#35. Can I use DOAC in a patient with renal disease? - The ...
Which medication should we use to prevent stroke in this patient? ... only two DOACs with FDA approval for patients undergoing hemodialysis.
#36. The Use of Rivaroxaban in Patients With Atrial Fibrillation ...
Specifically, a remark made in recommendation 54 (end-stage renal disease [ESRD]), which states “NOACs [novel oral anticoagulants] should ...
#37. Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients ...
NOACs have not been well-studied in patients with AF on dialysis. Current AF guidelines do not recommend the use of dabigatran, rivaroxaban, ...
#38. Rivaroxaban Versus Warfarin in Patients With Nonvalvular ...
provide desperate recommendations for the use of NOACs in patients ... 30 and 15 mL/min and recommend against their use in hemodialysis.
#39. Know When to Hold 'Em: Anticoagulation Management in ...
The recent surge in the use of novel oral anticoagulants (NOACs) adds ... Dabigatran should be avoided in dialysis-dependent patients with ...
#40. Use of oral anticoagulants in patients with atrial fibrillation and ...
the risks and benefits of use of VKAs and NOACs for ... patients with AF and CKD not requiring dialysis had.
#41. 1 Prevention and treatment of stroke in patients with chronic ...
Key words: Chronic Kidney Disease; Stroke; Dialysis; Primary Prevention; ... However, NOAC use in dialysis patients appears promising from observational ...
#42. Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients ...
of dabigatran and rivaroxaban use among 29,977 hemodialysis patients with atrial ... anticoagulant drugs (NOAC) in dialysis patients is currently ...
#43. Outcomes Associated with Apixaban Use in End ... - NephJC
Retrospective analysis of apixaban vs warfarin for atrial fibrillation in dialysis patients.
#44. Direct Oral Anticoagulants in Renal Disease
Use of NOACs in Patients with Atrial Fibrillation ... hemodialysis and accumulates quickly in ESRD patients. CrCl. > 50ml/min. 15-50 ml/min.
#45. Anticoagulation for atrial fibrillation in dialysis patients - Heart ...
recommendations encourage warfarin use with similar indications as ... atrial fibrillation on hemodialysis, including the role of NOACs or ...
#46. Apixaban in End-stage Kidney Disease : A Pharmacokinetics ...
An important benefit of apixaban as compared to other recent NOACs, ... Conventional anticoagulation used for hemodialysis is by heparin or low molecular ...
#47. Case Report: Apixaban in End Stage Renal Disease Causing ...
Here, we report the case of an elderly Caucasian female on hemodialysis who ... Aspirin use with a novel anticoagulant (NOAC) significantly increases the ...
#48. Apixaban as a therapeutic option in chronic kidney disease ...
the only new oral anticiagulant (NOAC) used in our hospital ... evant in patients undergoing hemodialysis, since they.
#49. Docs Still in Dark on Anticoagulant Choice in Severe Kidney ...
Although NOACs offer "similar or greater benefit" over ... apixaban with warfarin in participants with hemodialysis-dependent ESRD and AF, ...
#50. Dose-finding study of rivaroxaban in hemodialysis patients.
BACKGROUND Use of vitamin K antagonists for the prevention of stroke and systemic embolism in dialysis patients with nonvalvular atrial ...
#51. Nonvitamin K Anticoagulant Agents in ... - JACC Journals
It therefore remains unclear how or if NOACs should be prescribed to patients with advanced chronic kidney disease and those on dialysis.
#52. NOACs and Renal Impairment: Addressing Common Concerns
Dosing recommendations for different NOACs in patients with renal ... of the distinct dosing guidance for renal impairment for NOAC use in ...
#53. Anticoagulant strategies for the patient with chronic kidney ...
Long-term warfarin use is, however, associated with accelerated vascular ... In contrast to other NOACs, dabigatran is removable via haemodialysis, ...
#54. Effect of anticoagulation therapy in older patients with chr...
Moreover, AF patients on dialysis need routine heparin anticoagulant therapy during ... The anticoagulants used were VKAs (9184, 91.9%), NOACs (726, 7.3%), ...
#55. Use of Rivaroxaban and Apixaban, Two Non-Vitamin K ...
To understand the in luence of renal function on NOAC use, apixaban and ... Renal Disease (ESRD: CrCl <15 ml/min) and on dialysis are ...
#56. Oral anticoagulation 'reasonable' in advanced kidney disease ...
The novel direct-acting oral anticoagulants (NOACs) and warfarin were ... advanced CKD who were on dialysis, use of an OAC was once again a ...
#57. Thrombosis and anticoagulation in the setting of renal or liver ...
Therefore, specific anticoagulants may require dose reductions or be ... Warfarin use in hemodialysis patients: what is the risk?
#58. Direct Acting Oral Anticoagulants (DOACs) in Renal Impairment
Direct Acting Oral Anticoagulants (DOACs) in Renal Impairment: Practice Guide to Dosing Issues ... Choosing the correct dose of an anticoagulant ...
#59. Oral Anticoagulation for Patients With Atrial Fibrillation on ...
However, apixaban should be compared with no anticoagulant because whether to use anticoagulation therapy for patients with AF on long-term dialysis is still ...
#60. New Anticoagulants in Chronic Kidney Disease: A Beacon in ...
Dosing Recommendations for NOACs by International Regulatory ... calls into question the role of warfarin for NVAF in our dialysis patients.
#61. Dabigatran, rivaroxaban and apixaban, the new oral ...
to benefit from a NOAC, and to provide advice on using the NOACs in the safest possible ... Dialysis. Can be dialysed. (however extreme caution is advised.
#62. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial ...
However, use of oral anticoagulants for stroke prevention in ... bound and it is the only NOAC that can be removed with hemodialysis.
#63. Atrial fibrillation in patients with end‐stage renal disease on ...
afib), and anticoagulation (eg, oral anticoagulation, DOAC, NOAC, antithrombotics) were used to search the MEDLINE database. The.
#64. 2018 대한부정맥학회 심방세동 환자에서 NOAC 사용 지침 ...
2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to ...
#65. Benefits and Harms of Oral Anticoagulant Therapy in Chronic ...
In early-stage CKD, NOACs had a benefit–risk profile superior to that ... Use of warfarin in patients receiving dialysis who have AF varies ...
#66. Anticoagulation for Stroke Prevention in Older Adults with ...
Frailty; Warfarin; NOAC; Stroke; Bleeding ... on clinical outcomes with use of apixaban in dialysis-dependent ESRD patients is very limited.
#67. Apixaban versus Warfarin in Patients with Chronic Kidney ...
NOAC 제제 중에서 edoxaban과 apixaban은 serum creatinine ≥1.5 mg/dL 또는 ... Safety and efficacy of apixaban use in peritoneal dialysis: A ...
#68. Anticoagulating atrial fibrillation patients: is there a kidney ...
Notably, a study using Nationwide Inpatient Sample in the United States reported that dialysis-requiring acute kidney injury (AKI) increased from 0.3 to 1.5 per ...
#69. Eliquis (apixaban) 2.5 and 5 mg Tablets. - Accessdata.fda.gov
No data inform use in patients with creatinine clearance <15 mL/min or on dialysis.” To. “The dosing adjustment for moderate renal impairment is ...
#70. Nonvitamin K Anticoagulant Treatment in Patients With Atrial ...
Risks and benefits of nonvitamin K anticoagulant use in patients with atrial ... “NOAC use in patients with advanced CKD and on dialysis is ...
#71. Judging the Use of Novel Oral Anticoagulants for Atrial ...
No clear benefit or risk associated with the use of warfarin in AF patients on dialysis. Table 9: Renal Population in NOAC Drug Approval ...
#72. SIR-RFS Webinar (9/2/14): Anticoagulation for treatment of ...
... evidence for the use of low molecular weight heparin (LMWH) as a treatment for deep venous thrombosis in ESRD patients on hemodialysis, ...
#73. Practical guidance on NOACs and safety: How to deal with ...
Latest frontiers in anticoagulation therapy (3/4). 15' education - Feb. 20, 2018 - Prof. John Eikelboom, prof. Saskia Middeldorp, Dr. Hanna ...
#74. NOACs: How Choice Feeds Confusion | MedPage Today
With four new oral anticoagulants (NOACs) to chose from, ... and being the only one approved for use in patients on chronic hemodialysis, ...
#75. Which anticoagulant is safe in renal failure? - Movie Cultists
All of the NOACs are dependent on renal clearance to some degree and so the risk of NOAC associated bleeding may ... Why is anticoagulant used in dialysis?
#76. Thrombosis Research
The use of NOACs in end-stage renal disease (ESRD) patients on maintenance hemodialysis is further complicated by an additional.
#77. New oral anticoagulant drugs associated with lower kidney ...
... could lead to kidney failure, dialysis and potentially death. ... The researchers used the OptumLabs Data Warehouse, which includes ...
#78. The impact on renal function after long-term use of ...
Data on general demographics, comorbidities, baseline, and follow-up eGFR, medication use, presence of AKI, the need for hemodialysis, ...
#79. Bleeding Outcomes Using Novel Oral Anticoagulants (NOACs ...
Patients required a documented diagnosis of ESRD on hemodialysis and must have received at least one dose of anticoagulation to be included in ...
#80. or twice-daily dosing of non-vitamin K antagonist oral ...
In summary, the once-daily dose of NOACs was associated with increased patient ... of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with ...
#81. Oral Anticoagulation in 2017 - The Bangkok Medical Journal
Finally, we will discuss the practical use of NOACs in dailypractice ... of approximately 35%, which allows the eliminationof dabigatran by hemodialysis. 16.
#82. EM in 5: NOACs – Novel Oral Anticoagulants - emDocs
EM in 5: NOACs – Novel Oral Anticoagulants. Mar 19th, 2018; Anna Pickens; categories: EMin5. Author: Anna Pickens, MD (@AnnaEMin5, Creator of EM in 5) ...
#83. Choice of antithrombotic therapy for patients with atrial ...
... triple therapy with dual antiplatelet and one anticoagulation agent should be used briefly, with caution. Then changing to treatment with one NOAC and ...
#84. Dosing - NVAF | XARELTO® (rivaroxaban) HCP
Clinical efficacy and safety studies with XARELTO ® did not enroll patients with end-stage renal disease (ESRD) on dialysis. Pediatric Patients: ...
#85. New Oral Anticoagulants (NOACs) Dabigatran ... - SlidePlayer
Topics Trials Summary Trials Issues Advantages and Disadvantages of NOACs compared to Warfarin Effect on Coagulation Tests Cardioversion/ Invasive ...
#86. Oral Factor Xa Inhibitors versus Warfarin for the Treatment of ...
Although apixaban and rivaroxaban are both FDA approved for use in ESRD with dialysis, these approvals are not based on thromboembolic risks ...
#87. Nephrocardiology, An Issue of Cardiology Clinics, E-Book
... AF with ESRD on hemodialysis Assess the hemorrhagic and thrombotic risks ... According to the 2019 AHA/ACC/HRS guidelines, the use of NOACs for stroke ...
#88. Anticoagulation In Dialysis Patients: Clear As Mud - The Early ...
Apixaban was approved by the FDA in 2014 for use in ESRD patients, ... who manage heparin anticoagulation during hemodialysis treatments and ...
#89. Trauma Induced Coagulopathy - 第 535 頁 - Google 圖書結果
Specific antidotes to antagonize the anticoagulant effect of NOACs are currently available for ... Exposure to dabigatran can be reduced using dialysis.
#90. Pediatric Kidney Disease - 第 814 頁 - Google 圖書結果
Regarding the use of NOAC in children, they are indicated mostly in the event of an ... be used for children requiring hemodialysis who develop HIT, ...
#91. Advances in Trauma, An Issue of Critical Care Clinics
In terms of its studied use with NOACs, activated charcoal has been found to ... or nasogastric route.9 Hemodialysis For the urgent reversal of dabigatran, ...
#92. Outcomes of Cardiovascular Drug Use in the Older Population
These findings suggest that NOACs can be used for patients with ... apixaban was approved for application in hemodialysis patients in 2014 (Undas et al., ...
#93. Management of Cardiovascular Disease, An Issue of Medical ...
Dabigatran, which is primarily cleared renally, may not be the NOAC of first ... Malignancy Malignancy and AF occur in the elderly, and the use of NOACs in ...
#94. New Insights in Intracerebral Hemorrhage - 第 47 頁 - Google 圖書結果
Limited data have been published on the use of oral activated charcoal in the setting ... Hemodialysis Dabigatran has relatively low plasma protein binding, ...
noac use in hemodialysis 在 SIR-RFS Webinar (9/2/14): Anticoagulation for treatment of ... 的推薦與評價
... evidence for the use of low molecular weight heparin (LMWH) as a treatment for deep venous thrombosis in ESRD patients on hemodialysis, ... ... <看更多>